

**Washington State Pharmacy and Therapeutics Committee
Drug Utilization Review Board
Date: June 17, 2020
Time: 9 a.m. to 4 p.m.
GoTo Webinar**

9 a.m.	Welcome & Introductions Pharmacy and Therapeutics (P&T) Committee Convenes	Ginni Buccola, Committee Chair
9:05 a.m.	TIMs- Crohns Disease, Ulcerative Colitis • Stakeholder input*	Leila Kahwati, DERP
9:50 a.m.	TIMs- Rheumatoid Arthritis, Ankylosing Spondylitis • Stakeholder input*	Gerald Gartlehner, DERP
10:35 a.m.	Break	All
10:45 a.m.	TIMs- Plaque Psoriasis, Psoriatic Arthritis • Stakeholder input* • Motion	Leila Kahwati, DERP
11:35 a.m.	Pharmacy and Therapeutics (P&T) Committee Adjourns Lunch	Ginni Buccola, Committee Chair All
12:05 p.m.	Drug Utilization Review (DUR) Board Convenes	Ginni Buccola, Committee Chair
12:05 p.m.	Oncology: Oral-Hematologic • Stakeholder input* • Motion	Umang Patel, Magellan
12:40 p.m.	Cytokine & CAM Antagonists • Stakeholder input* • Motion	Umang Patel, Magellan
1:25 p.m.	Erythropoiesis Stimulating Proteins • Stakeholder input* • Motion	Umang Patel, Magellan
1:40 p.m.	Colony Stimulating Factors • Stakeholder input* • Motion	Umang Patel, Magellan
1:55 p.m.	Break	All
2:05 p.m.	Sickle Cell Anemia Treatments • Stakeholder input* • Motion	Umang Patel, Magellan
2:35 p.m.	Apple Health Policy- Oncology: Radiopharmaceuticals- Lutetium Lu 177 dotatate (Lutathera) • Stakeholder input* • Motion	Luke Dearden, HCA
2:50 p.m.	Apple Health Policy- Androgenic Agents- Testosterone Replacement Therapy (TRT) • Stakeholder input* • Motion	Ryan Pistoressi, HCA

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.

3:05 p.m.	Apple Health Policy- Endocrine and Metabolic Agents- Elapegedemase-lvlr (Revcovi) <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Marissa Tabile, HCA
3:20 p.m.	Apple Health Policy- Endocrine and Metabolic Agents- Burosumab-twza (Crysvita) <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Ryan Taketomo, HCA
3:35 p.m.	Apple Health Policy- Agents for ALS- Edaravone (Radicava) <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Ryan Taketomo, HCA
3:45 p.m.	Apple Health Policy- Ophthalmic Agents: Gene Therapy- Voretigene neparvovec-rzyl (Luxturna) <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Marissa Tabile, HCA
4 p.m.	Drug Utilization Review Board Adjourns	Ginni Buccola, Committee Chair

For all Apple Health (Medicaid) questions, please email AppleHealthPharmacyPolicy@hca.wa.gov

** Stakeholders will be allowed 3 minutes for comments.
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.